Inovio announces first patient dosed in trial of PENNVAX®-GP for HIV infection
Inovio announced the first participant has been dosed with PENNVAX®-GP in a randomized clinical trial that will evaluate its ability to drive remission of HIV infection. This vaccine widely targets all major HIV strains and the potential to enhance the capacity of the immune system. August 14, 2018